Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial

Abstract

In this randomized study, a treatment switch to atazanavir/ritonavir + lamivudine was superior over the continuation of atazanavir/ritonavir + 2NRTI in virologically suppressed patients, with a sustained benefit in terms of improved renal function and bone mineral density.

References

Page 1

	Year	Citations
Updated research nosology for HIV-associated neurocognitive disorders Andrea Antinori, Gabriele Arendt, James T. Becker, Neurology NeuropsychologyBrain FunctionNeurological DisorderClinical NeurologyResearch Nosology	2007	2.6K
Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients Anne‐Marie Taburet, Christophe Piketty, Corine Chazallon, Antimicrobial Agents and Chemotherapy Antiviral CompoundHuman RetrovirusImmunologyPharmacologyResistance Mutation (Virology)	2004	211
Brief Report David A. Wohl, Shinichi Oka, Nathan Clumeck, JAIDS Journal of Acquired Immune Deficiency Syndromes Double-blinded Phase 3Initial Hiv-1 TreatmentTaf ArmTreatment And PreventionMedicine	2016	178
Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level Jean‐Paul Viard, Marianne Burgard, Jean‐Baptiste Hubert, AIDS	2004	178
Recommendations for Evaluation and Management of Bone Disease in HIV Todd T. Brown, Jennifer Hoy, Marco Borderi, Clinical Infectious Diseases	2015	178
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial Pedro Cahn, Jaime Andrade‐Villanueva, José Ramón Arribas, The Lancet Infectious Diseases Open LabelHuman RetrovirusAntiviral Drug DevelopmentClinical TrialsAntiviral Therapy	2014	154
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial José Ramón Arribas, Pierre‐Marie Girard, Roland Landman, The Lancet Infectious Diseases Hiv/aids CounsellingHuman RetrovirusAntiviral Drug DevelopmentAntiviral TherapyVirology	2015	142
Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero, The Lancet Infectious Diseases Hiv/aids CounsellingTreatment And PreventionNeurovirologyHuman RetrovirusImmunology	2015	130
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results José Ramón Arribas, Melanie Thompson, Paul E. Sax, JAIDS Journal of Acquired Immune Deficiency Syndromes PharmacotherapyTenofovir AlafenamideAntiviral DrugHuman RetrovirusAntiviral Drug Development	2017	116
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial Federico Pulido, Esteban Ribera, María Lagarde, Clinical Infectious Diseases	2017	102

Page 1